Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

Next Previous
Trial Profile

An International, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ganitumab (Primary) ; Exemestane; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Amgen

Most Recent Events

  • 12 Feb 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
  • 03 Jul 2012 Planned number of patients changed from 150 to 156 as reported by European Clinical Trials Database record.
  • 25 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top